Inmunobiología e inmunomodulación parasitaria
INMUNOPAR
![Foto de Inmunobiología e inmunomodulación parasitaria](/img/grupo.png)
![Foto de University of Portsmouth](/img/noimage_org.png)
University of Portsmouth
Portsmouth, Reino UnidoPublicacions en col·laboració amb investigadors/es de University of Portsmouth (7)
2020
-
Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis
International Journal of Pharmaceutics, Vol. 588
-
Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale
International Journal of Pharmaceutics, Vol. 573
-
Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases
ACS Infectious Diseases, Vol. 6, Núm. 10, pp. 2647-2660
2019
-
Repurposing butenafine as an oral nanomedicine for visceral leishmaniasis
Pharmaceutics, Vol. 11, Núm. 7
2018
-
Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis
Molecular Pharmaceutics, Vol. 15, Núm. 7, pp. 2570-2583
2017
-
Engineering oral and parenteral amorphous amphotericin B formulations against experimental Trypanosoma cruzi infections
Molecular Pharmaceutics, Vol. 14, Núm. 4, pp. 1095-1106
2015
-
Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles
Molecular Pharmaceutics, Vol. 12, Núm. 2, pp. 420-431